C Florescu1, J Thariat2. 1. Service de Radiothérapie, Centre Fran¸cois Baclesse, Avenue Général Harris, 14076, Caen, France. 2. Centre Antoine Lacassagne - Université de Nice Sophia Antipolis, 227 Av de la lanterne, 06200, Nice, France. Electronic address: jthariat@hotmail.com.
Abstract
BACKGROUND: Median survival for recurrent/metastatic (unknown poly/oligometastatic status) head and neck cancer patients (HNSCC) is ten months with best systemic treatment. Metastatic ablation shows promising results in selected patients with several tumor types. We aimed to assess the role of surgery and stereotactic ablative body radiotherapy (SABR) with respect to survival in HNSCC. MATERIALS AND METHODS: Published data on metastatic HNSCC treated ablatively were analyzed. RESULTS: Five-year survival rates after pulmonary/liver metastasectomy exceed 20% in selected patients. Two-year survival after lung SABRT of metastasectomy yields 35%. Interesting data on survival and tolerance are reported in other metastatic sites. CONCLUSION: Surgery yields the best level of evidence. However, non-invasive SABR is efficient and well-tolerated in lung/liver, bone and other metastatic locations. Systemic treatment may be given sequentially with ablative treatments, or omitted in well-identified situations. Proper patient selection for local ablative treatment and optimal therapeutic sequence should be assessed in randomized trials.
BACKGROUND: Median survival for recurrent/metastatic (unknown poly/oligometastatic status) head and neck cancerpatients (HNSCC) is ten months with best systemic treatment. Metastatic ablation shows promising results in selected patients with several tumor types. We aimed to assess the role of surgery and stereotactic ablative body radiotherapy (SABR) with respect to survival in HNSCC. MATERIALS AND METHODS: Published data on metastatic HNSCC treated ablatively were analyzed. RESULTS: Five-year survival rates after pulmonary/liver metastasectomy exceed 20% in selected patients. Two-year survival after lung SABRT of metastasectomy yields 35%. Interesting data on survival and tolerance are reported in other metastatic sites. CONCLUSION: Surgery yields the best level of evidence. However, non-invasive SABR is efficient and well-tolerated in lung/liver, bone and other metastatic locations. Systemic treatment may be given sequentially with ablative treatments, or omitted in well-identified situations. Proper patient selection for local ablative treatment and optimal therapeutic sequence should be assessed in randomized trials.
Keywords:
Head and neck cancer; Isolated; Limited; Local treatment; Metastasectomy; Metastases; Metastasis; SBRT); Stereotactic irradiation (SABR; Surgery
Authors: Luluel Khan; Michael Tjong; Hamid Raziee; Justin Lee; Darby Erler; Lee Chin; Ian Poon Journal: Support Care Cancer Date: 2014-10-09 Impact factor: 3.603
Authors: J Madana; Gregoire B Morand; Luz Barona-Lleo; Martin J Black; Alex M Mlynarek; Michael P Hier Journal: J Otolaryngol Head Neck Surg Date: 2015-02-04
Authors: Zachary G Schwam; Barbara Burtness; Wendell G Yarbrough; Saral Mehra; Zain Husain; Benjamin L Judson Journal: Cancer Med Date: 2015-10-16 Impact factor: 4.452
Authors: Salvatore Grisanti; Susanna Bianchi; Laura D Locati; Luca Triggiani; Stefania Vecchio; Alberto Bonetta; Cristiana Bergamini; Pierfranco Conte; Mario Airoldi; Marco Merlano; Paolo Carlini; Toni Ibrahim; Ciro Rossetto; Salvatore Alfieri; Paolo Pronzato; Sandro Tonoli; Roberto Maroldi; Piero Nicolai; Carlo Resteghini; Stefano M Magrini; Alfredo Berruti Journal: PLoS One Date: 2019-03-20 Impact factor: 3.240
Authors: Ciro Franzese; M Badalamenti; A Teriaca; A De Virgilio; G Mercante; R Cavina; D Ferrari; A Santoro; G Spriano; M Scorsetti Journal: J Cancer Res Clin Oncol Date: 2021-01-20 Impact factor: 4.553